Indication intelligence, analysis and sector perception

RegMed’s close: sentiment is flashing danger signals

November 11, 2015 6:10pm

There is no surprise to see stock testing their previous low.

I see tax selling opportunity increasing.

Subscription required, read more … http://www.regmedinvestors.com/user/register

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

U.S. stocks ended Wednesday’s thinly-traded session lower as a selloff in energy shares that were triggered by a drop in oil prices weighed on the main indexes. Trading volumes were lower than usual as bond markets and banks are closed in observance of Veterans Day.

The NASDAQ closed DOWN -16.22 or -0.32% to 5,067.02 and the DOW or -55.99 or -0.32% to 17,702.22.

Henry’omics:

Back to my … sentiment conversations: Investor naivety and fantasy about some sector “participants” reflect a contrarian indicator. A little pessimism is good for stocks, while excessive optimism tends to be negative for stocks;

Paradoxically, a lack of investor sentiment enables sellers generating an influx of traders … and extends the life of this carousel oriented sector mechanics lacking any expectation.

The stem, cell and gene therapy RegMed sector opened negative flipped to the upside by 1 (of 43 covered companies) to close in negative territory

My fear gauge – The CBOE Volatility Index (VIX) closed Wednesday near 16 having barely moved on Tuesday to near 15 from Monday’s below 15 following Friday’s above 16.

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

The SCGT & RM equities opened negative with an Advance/Decline line (A/DL) of 14/26 and 3 flats;

The mid-day popped to a positive A/DL of 20/19 and 4 flats;

The closing bell rang negative to end the session with an A/DL of 14/27 and 2 flats.

Tuesday’s trading indications: 3 hits/ 2 miss

Bellicum Pharma (BLCM) closed UP – hit;
Kite Pharma (KITE) closed DOWN – miss;
Opexa (OPXA) closed UP - hit;
Osiris (OSIR) closed UP – hit;
Verastem (VSTM) closed DOWN – miss;

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed DOWN on Wednesday -5.11 or -1.54% after Tuesday’s +1.38 or +0.42% following Monday’s advance of +0.34 or +0.10%;

The NASDAQ Biotechnology index (NBI) closed DOWN -49.32 or -1.42% after Tuesday‘s advance of 13.99 or +0.40% following Monday’s advance of +2.30 or +0.07%;

The Russell 2000 (IWM) closed DOWN on Wednesday -1.03 or -0.87% after Tuesday’s +0.35 or +0.30% following Monday’s decline of -1.40 or -1.17%;

The SPDR SD&P Biotech ETF (XBI) closed DOWN -1.20 or -1.69% on Wednesday after Tuesday’s decline of -0.25 or -0.35% following Monday’s advance of +0.63 or +0.89%;

Dosing the sector – what a day for the 43 Patients:

Open: NEGATIVE with 26 decliners, 14 advances and 3 flats;

Mid-day (1 pm): POSITIVE with 19 decliners, 20 advancers and 4 flats;

Closing bell: NEGATIVE with 24 decliner, 17 advancers and 2 flats

Who was UP – top 5:

Regenxbio (RGNX) closed up +$1.45 to $22.98;
uniQure (QURE) +$1.03 to $20.57;
Spark Therapeutics (ONCE) +$0.55 to $60.26;
Juno Therapeutics (JUNO) +$0.45 to $52.28;
Osiris (OSIR) closed up +$0.29 to $14.63

Who closed down – top 5:

Aduro Biotech (ADRO) closed down -$1.62 to $28.26;
Intrexon (XON) -$1.04 to $41.76;
Kite Pharma (KITE) -$1.03 to $61.64;
Bluebird bio (BLUE) -$0.93 to $74.30;
Cellectis ADR (CLLS) closed down -$0.60 to $37.03;

Flat:

Stemline (STML) at $8.96;
Mesoblast ADR (USOTC: MBLTY) at $12.33;

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.